CY1112699T1 - Ηcv νs5β αναστολεις τυπου κυκλοπροπυλο συγχωνευμενης ινδολοβενζαζεπινης - Google Patents

Ηcv νs5β αναστολεις τυπου κυκλοπροπυλο συγχωνευμενης ινδολοβενζαζεπινης

Info

Publication number
CY1112699T1
CY1112699T1 CY20121100152T CY121100152T CY1112699T1 CY 1112699 T1 CY1112699 T1 CY 1112699T1 CY 20121100152 T CY20121100152 T CY 20121100152T CY 121100152 T CY121100152 T CY 121100152T CY 1112699 T1 CY1112699 T1 CY 1112699T1
Authority
CY
Cyprus
Prior art keywords
indolobenzazepin
cyclopropyple
cyclone
consolidated
hcv ns5b
Prior art date
Application number
CY20121100152T
Other languages
English (en)
Inventor
John A Bender
Min Ding
Robert G Gentles
Piyasena Hewawasam
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1112699T1 publication Critical patent/CY1112699T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση περιλαμβάνει ενώσεις του τύπου (Ι) καθώς και συνθέσεις και μεθόδους χρήσης των ενώσεων. Οι ενώσεις είναι δραστικές έναντι ιού ηπατίτιδας C (ΗCV) και είναι χρήσιμες στην αγωγή ατόμων μολυσμένων με ΗCV.
CY20121100152T 2007-11-20 2012-02-14 Ηcv νs5β αναστολεις τυπου κυκλοπροπυλο συγχωνευμενης ινδολοβενζαζεπινης CY1112699T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2007/085183 WO2009067108A1 (en) 2007-11-20 2007-11-20 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
EP07874300A EP2209789B1 (en) 2007-11-20 2007-11-20 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
CY1112699T1 true CY1112699T1 (el) 2016-02-10

Family

ID=40010653

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100152T CY1112699T1 (el) 2007-11-20 2012-02-14 Ηcv νs5β αναστολεις τυπου κυκλοπροπυλο συγχωνευμενης ινδολοβενζαζεπινης

Country Status (14)

Country Link
EP (1) EP2209789B1 (el)
JP (1) JP5416710B2 (el)
KR (1) KR20100108341A (el)
CN (1) CN101918410B (el)
AT (1) ATE533771T1 (el)
AU (1) AU2007361468A1 (el)
CY (1) CY1112699T1 (el)
DK (1) DK2209789T3 (el)
ES (1) ES2375065T3 (el)
MX (1) MX2010005226A (el)
PL (1) PL2209789T3 (el)
PT (1) PT2209789E (el)
SI (1) SI2209789T1 (el)
WO (1) WO2009067108A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
EP2276764B1 (en) 2008-03-27 2013-07-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
CN102046630A (zh) 2008-03-27 2011-05-04 百时美施贵宝公司 吡咯烷稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
EA201390988A1 (ru) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3413915A1 (en) 2016-02-08 2018-12-19 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting her2 tumours and method for improving therapeutic index of antibody-conjugates
WO2017137423A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Improved sulfamide linkers for use in bioconjugates
US11951175B2 (en) 2016-02-08 2024-04-09 Synaffix B.V. Bioconjugates containing sulfamide linkers for use in treatment
EP3429355B1 (de) 2016-03-15 2020-02-05 Bayer CropScience AG Substituierte sulfonylamide zur bekämpfung tierischer schädlinge
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
EP4055010A1 (de) 2019-11-07 2022-09-14 Bayer Aktiengesellschaft Substituierte sulfonylamide zur bekämpfung tierischer schädlinge

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100387580C (zh) * 1997-09-29 2008-05-14 明治制果株式会社 三环三唑并苯并氮杂䓬衍生物、用于制备该衍生物的方法和抗变态反应剂
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140254A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
EP2121707B1 (en) * 2006-12-20 2012-12-05 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Antiviral indoles
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2008111978A1 (en) * 2007-03-13 2008-09-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
SI2209789T1 (sl) 2012-06-29
EP2209789A1 (en) 2010-07-28
DK2209789T3 (da) 2012-03-05
WO2009067108A1 (en) 2009-05-28
ATE533771T1 (de) 2011-12-15
EP2209789B1 (en) 2011-11-16
JP5416710B2 (ja) 2014-02-12
ES2375065T3 (es) 2012-02-24
CN101918410B (zh) 2013-02-27
JP2011503229A (ja) 2011-01-27
CN101918410A (zh) 2010-12-15
MX2010005226A (es) 2010-05-27
AU2007361468A1 (en) 2009-05-28
PL2209789T3 (pl) 2012-04-30
KR20100108341A (ko) 2010-10-06
PT2209789E (pt) 2012-01-16

Similar Documents

Publication Publication Date Title
CY1112699T1 (el) Ηcv νs5β αναστολεις τυπου κυκλοπροπυλο συγχωνευμενης ινδολοβενζαζεπινης
CY1111423T1 (el) Αναστολεις ns5b hcv
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
CY1113752T1 (el) Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
ATE492558T1 (de) Makrocyclische peptide als hepatitis-c-virus- hemmer
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
EA201390538A1 (ru) Противовирусные соединения
ATE492559T1 (de) Makrocyclische peptide als hepatitis-c-virus- hemmer
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
MX2010010235A (es) Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.
UA95990C2 (en) Hcv ns3 protease inhibitors
ATE531373T1 (de) Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
MX2010010245A (es) Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a dioxolano y dioxolanona.